IDEXX Laboratories stock gains 1.16 percent as valuation holds

Published on 09/22/2026 at 18:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

IDEXX Laboratories stock closed at USD 517.57 on September 21, 2026, up 1.16 percent. Market capitalization stood at USD 40.60 billion.

Moderne Veterinärdiagnostik-Labor mit Analysegeräten, Blutproben und Technikerin — IDEXX Laboratories US45168D1046 zeigt ein modernes Veterinärdiagnostik Labor mit Analysegeräten und Technikerin, Illustration mit AI erstellt.

IDEXX Laboratories stock (ISIN US45168D1046) closed at USD 517.57 on Nasdaq on September 21, 2026, gaining 1.16 percent from the previous session. The move placed the veterinary diagnostics company above its recent support area and kept the shares within the lower part of their 52-week range.

Stock gains with market support

The September 21 close followed a session in which IDEXX Laboratories finished near the upper part of its daily range, according to IT BOLTWISE on September 22, 2026. The report also placed the move in the broader performance of US growth and quality shares rather than linking it to a specific company announcement.

Market data from Pluang put IDEXX Laboratories at USD 522.81 in its comparison snapshot on September 22, 2026, with a market capitalization of USD 40.60 billion, volume of 508,758 shares, a 52-week high of USD 766.68 and a 52-week low of USD 504.70. The spread between the high and low shows that the latest quote remained USD 261.98 below the yearly peak while staying USD 18.11 above the yearly low.

Growth figures support valuation

Pluang reported revenue of USD 4.3 billion for 2025 and projected USD 4.6 billion for 2026, a difference of USD 0.3 billion or about 7.0 percent. The same source cited a projected net income margin of 24.61 percent for 2026 and described recent earnings as above estimates, while also noting raised 2026 EPS guidance.

The operating profile remains tied to recurring veterinary diagnostics, laboratory services, instruments and practice-management software. Pluang said IDEXX Laboratories generates about 38 percent of revenue outside the United States, giving international demand an important role while also leaving the business exposed to foreign-exchange effects.

The valuation remains demanding beside the operating figures. Pluang listed a price-to-earnings ratio of 35.96 and a consensus price target of USD 665 based on 13 buy ratings on September 22, 2026. That target stood USD 142.19 above the comparison price of USD 522.81, while the source also identified insider selling and technical weakness as counter-factors.

Premium valuation meets technical risk

The central investor tension is therefore numerical: projected 2026 revenue growth of about 7.0 percent stands against a price-to-earnings ratio of 35.96. The share price gained 1.16 percent on September 21, yet the USD 504.70 to USD 766.68 52-week range shows that the stock remains far below its yearly high.

For investors, the next assessment point is whether the company can convert the projected USD 4.6 billion in 2026 revenue and the raised EPS outlook into continued earnings beats. The current data combine operating growth with a premium multiple, so earnings delivery remains more important than the one-day price change.

Nasdaq price remains above yearly low

IDEXX Laboratories closed at USD 517.57 on Nasdaq on September 21, 2026, up 1.16 percent from the prior session. A separate September 22 market snapshot showed USD 522.81, market capitalization of USD 40.60 billion and volume of 508,758 shares.